Abstract
Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects*
-
Brain / pathology*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary
-
Diagnosis, Differential
-
Female
-
Headache / etiology
-
Humans
-
Indoles / administration & dosage
-
Indoles / adverse effects*
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / pathology
-
Magnetic Resonance Imaging
-
Middle Aged
-
Posterior Leukoencephalopathy Syndrome / chemically induced*
-
Posterior Leukoencephalopathy Syndrome / complications
-
Posterior Leukoencephalopathy Syndrome / diagnosis*
-
Posterior Leukoencephalopathy Syndrome / pathology
-
Pyrroles / administration & dosage
-
Pyrroles / adverse effects*
-
Seizures / etiology
-
Sunitinib
Substances
-
Angiogenesis Inhibitors
-
Indoles
-
Pyrroles
-
Sunitinib